Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Keros Therapeutics, Inc. (KROS)
USD10.77
+0.20 (+1.88%)
US NASDAQ Healthcare Biotechnology
Address
99 Hayden Avenue 2421
Lexington, MA, US
Lexington, MA, US
CEO
Jasbir S. Seehra
Website
kerostx.com
IPO
2020-04-08
CIK 1664710 ISIN US4923271013
Description
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD10.77
+0.20 (+1.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
334.3K
Beta
0.97
Float Shares
34.35M
Free Float %
92.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.46% | -12.86% | -10.03% | -36.44% | -39.55% | -48.43% | -25.53% | -77.27% | -79.38% | -47.71% | -47.71% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
10.77
Low
96.00
+791.5%
Consensus
102.60
+852.8%
Median
105.00
+875.0%
High
107.00
+893.6%
Ratings Trend (MoM)
56% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 7 |
101.86
+845.9%
|
Quality scores
Altman Z-Score
5.45
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✓ MOAT relativo
-
Revenue growth Biotechnology: +1.6%+6,775.0% ★ Q1'26: -99.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+146.0% ★ Q1'26: -117.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+22.0% Q1'26: -981.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+28.9% ★ Q1'26: -7,051.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+205.1% ★ Q1'26: -506.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.1% ★ Q1'26: -7.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.23× ★ Q1'26: -0.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 6 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.10M
est: 100.0K (+20,000.0%)
|
—
est: 1.00M (-100.0%)
|
151.0K
est: 271.0K (-44.3%)
|
3.55M
est: 554.0K (+540.8%)
|
244.06M
est: 245.93M (-0.8%)
|
3.95M
1.32M – 6.59M
-98.4% YoY
|
13.67M
816.6K – 26.51M
+245.7% YoY
|
58.12M
58.12M – 58.12M
+325.3% YoY
|
74.04M
8.25M – 139.83M
+27.4% YoY
|
114.88M
12.80M – 216.96M
+55.2% YoY
|
| EBITDA |
-56.35M
est: -20.0K (-281,669.1%)
|
-104.00M
est: -200.0K (-51,902.3%)
|
-152.18M
est: -92.4K (-164,627.6%)
|
-185.82M
est: -188.9K (-98,296.1%)
|
72.13M
est: -83.83M (+186.0%)
|
-1.35M
-2.25M – -449.1K
+98.4% YoY
|
-4.66M
-9.04M – -278.4K
-245.7% YoY
|
-19.81M
-19.81M – -19.81M
-325.3% YoY
|
-25.24M
-47.67M – -2.81M
-27.4% YoY
|
-39.16M
-73.96M – -4.36M
-55.2% YoY
|
| EBIT |
-56.73M
est: -20.0K (-283,559.2%)
|
-104.68M
est: -200.0K (-52,239.3%)
|
-152.99M
est: -92.7K (-164,911.4%)
|
-187.05M
est: -189.5K (-98,588.9%)
|
70.62M
est: -84.14M (+183.9%)
|
-1.35M
-2.25M – -450.7K
+98.4% YoY
|
-4.68M
-9.07M – -279.4K
-245.7% YoY
|
-19.88M
-19.88M – -19.88M
-325.3% YoY
|
-25.33M
-47.84M – -2.82M
-27.4% YoY
|
-39.30M
-74.23M – -4.38M
-55.2% YoY
|
| Net Income |
-58.74M
est: -117.65M (+50.1%)
|
-104.68M
est: -155.86M (+32.8%)
|
-152.99M
est: -168.05M (+9.0%)
|
-187.35M
est: -107.55M (-74.2%)
|
87.01M
est: 92.44M (-5.9%)
|
-249.53M
-331.02M – -168.04M
-369.9% YoY
|
-229.28M
-303.16M – -155.40M
+8.1% YoY
|
-110.63M
-338.08M – -54.52M
+51.7% YoY
|
-148.35M
-319.72M – 23.02M
-34.1% YoY
|
-85.75M
-184.81M – 13.30M
+42.2% YoY
|
| SGA |
21.33M
est: 4.90M (+334.9%)
|
27.53M
est: 49.05M (-43.9%)
|
34.83M
est: 13.25M (+162.9%)
|
40.75M
est: 27.08M (+50.5%)
|
46.85M
est: 12.02B (-99.6%)
|
193.21M
64.40M – 322.02M
-98.4% YoY
|
668.01M
39.92M – 1.30B
+245.7% YoY
|
2.84B
2.84B – 2.84B
+325.3% YoY
|
3.62B
403.29M – 6.84B
+27.4% YoY
|
5.62B
625.76M – 10.61B
+55.2% YoY
|
| EPS |
-2.52
est: -3.14 (+19.8%)
|
-4.15
est: -4.16 (+0.3%)
|
-5.20
est: -5.11 (-1.8%)
|
-5.00
est: -5.19 (+3.6%)
|
2.34
est: 2.30 (+1.8%)
|
-5.98
-8.74 – -4.44
-360.1% YoY
|
-5.78
-8.01 – -4.10
+3.4% YoY
|
-3.95
-8.93 – -1.44
+31.6% YoY
|
-3.92
-8.45 – 0.61
+0.9% YoY
|
-2.27
-4.88 – 0.35
+42.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-04 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-01 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-30 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
181.76M
OE per share TTM
4.37
Owner's Yield
40.66%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
31.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
29
Total invested
9.87M
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 3.03M | 15.00% | 255.3K | — | 3.03M | — | HC | Delaware | 2020-11-10 | ↗ |
| 2 | Alon Lazarus | 2.04M | 8.79% | 23.0K | 2.01M | 23.0K | 10.00 | IN | Israel | 2020-12-17 | ↗ |
| 3 | Arkin Bio Venture Partners Ltd. | 1.81M | 7.55% | — | 1.81M | — | 1.81M | CO | Israel | 2022-04-12 | ↗ |
| 4 | Arkin Bio Ventures Limited Partnership | 1.81M | 7.55% | — | 1.81M | — | 1.81M | PN | Israel | 2022-04-12 | ↗ |
| 5 | Moshe Arkin | 1.81M | 7.55% | — | 1.81M | — | 1.81M | IN | Israel | 2022-04-12 | ↗ |
| 6 | Capital Fund IV, L.P. (“FCF IV”) | 1.41M | 6.10% | 1.41M | 1.41M | 1.41M | 1.41M | PN | — | 2021-02-16 | ↗ |
| 7 | Capital Management IV, LLC (“FCM IV”) | 1.41M | 6.10% | 1.41M | 1.41M | 1.41M | 1.41M | OO | — | 2021-02-16 | ↗ |
| 8 | James Tananbaum (“Tananbaum”) | 1.41M | 6.10% | 1.41M | 1.41M | 1.41M | 1.41M | IN | — | 2021-02-16 | ↗ |
| 9 | Arsani William | 1.35M | 11.00% | — | 1.35M | — | 1.35M | HC, IN | Delaware | 2020-08-31 | ↗ |
| 10 | Logos GP LLC | 1.35M | 11.00% | — | 1.35M | — | 1.35M | OO | Delaware | 2020-08-31 | ↗ |
| 11 | Logos Global Management GP LLC | 1.35M | 11.00% | — | 1.35M | — | 1.35M | HC, OO | Delaware | 2020-08-31 | ↗ |
| 12 | Logos Global Management LP | 1.35M | 11.00% | — | 1.35M | — | 1.35M | IA, PN | Delaware | 2020-08-31 | ↗ |
| 13 | Logos Global Master Fund LP | 1.35M | 11.00% | — | 1.35M | — | 1.35M | PN | Delaware | 2020-08-31 | ↗ |
| 14 | David Kroin | 1.30M | 5.50% | — | 1.30M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 15 | Deep Track Biotechnology Master Fund, Ltd. | 1.30M | 5.50% | — | 1.30M | — | — | CO | Cayman Islands | 2022-02-14 | ↗ |
| 16 | Deep Track Capital, LP | 1.30M | 5.50% | — | 1.30M | — | — | IA, OO | Delaware | 2022-02-14 | ↗ |
| 17 | (1) BlackRock, Inc. | 1.29M | 5.50% | 1.28M | — | 1.29M | — | HC | Delaware | 2022-02-03 | ↗ |
| 18 | OrbiMed Advisors LLC | 1.27M | 4.60% | — | 1.27M | — | 11.00 | IA | — | 2022-11-07 | ↗ |
| 19 | (1)Names of reporting persons. BlackRock, Inc. | 1.20M | 5.20% | 1.19M | — | 1.20M | — | HC | Delaware | 2021-02-02 | ↗ |
| 20 | OrbiMed Capital GP VII LLC | 1.12M | 4.10% | — | 1.12M | — | 10.00 | OO | Delaware | 2022-11-07 | ↗ |
| 21 | OrbiMed Capital LLC | 410.7K | 1.50% | 410.7K | — | 410.7K | 10.00 | IA | Cayman Islands | 2022-11-07 | ↗ |
| 22 | OrbiMed Genesis GP LLC | 148.9K | 0.50% | — | 148.9K | — | 10.00 | OO | Delaware | 2022-11-07 | ↗ |
| 23 | IV”) | — | 0.00% | — | — | — | — | OO | — | 2022-02-11 | ↗ |
| 24 | S James Tananbaum (“Tananbaum”) | — | 0.00% | — | — | — | — | IN | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
29
-141 vs prev Q
New positions
6
Closed positions
140
Increased
15
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 2.29M -426.6K (-15.7%) | 46.64M +3.6M (+8.5%) | 5.64% -1.052 pp | 0.00% +0.000 pp | USD55.64 -63.4% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 1.53M -1.2M (-43.9%) | 31.06M -12.0M (-27.8%) | 3.75% -2.940 pp | 0.00% 0.000 pp | USD35.90 -43.3% | 23 qtrs — |
| 3 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.33M +1.1M (+415.7%) | 27.17M +23.1M (+563.8%) | 3.29% +2.648 pp | 0.02% +0.013 pp | USD19.36 +5.2% | 3 qtrs — |
| 4 | STATE STREET CORP | 1.08M -227.0K (-17.4%) | 21.91M +1.3M (+6.3%) | 2.65% -0.560 pp | 0.00% +0.000 pp | USD46.59 -56.3% | 23 qtrs — |
| 5 | MADISON AVENUE PARTNERS, LP | 823.7K -1.9M (-69.6%) | 16.77M -26.1M (-60.9%) | 2.03% -4.641 pp | 0.72% -1.836 pp | USD13.37 +52.3% | 3 qtrs — |
| 6 | ORBIMED ADVISORS LLC | 804.2K -214.5K (-21.1%) | 16.37M +257.4K (+1.6%) | 1.98% -0.529 pp | 0.34% -0.044 pp | USD37.51 -45.7% | 23 qtrs — |
| 7 | QUBE RESEARCH & TECHNOLOGIES LTD | 783.9K +480.8K (+158.6%) | 15.96M +11.2M (+232.8%) | 1.93% +1.183 pp | 0.02% +0.011 pp | USD18.33 +11.1% | 15 qtrs — |
| 8 | JACOBS LEVY EQUITY MANAGEMENT, INC | 768.4K +161.3K (+26.6%) | 15.65M +6.0M (+62.9%) | 1.89% +0.397 pp | 0.06% +0.022 pp | USD15.09 +34.9% | 3 qtrs — |
| 9 | D. E. SHAW & CO., INC. | 755.5K -576.0K (-43.3%) | 15.38M -5.7M (-27.0%) | 1.86% -1.419 pp | 0.01% -0.004 pp | USD10.75 +89.4% | 8 qtrs — |
| 10 | FEDERATED HERMES, INC. | 654.7K +140.6K (+27.3%) | 13.33M +5.2M (+63.9%) | 1.61% +0.346 pp | 0.02% +0.008 pp | USD12.82 +58.8% | 5 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 635.2K -202.2K (-24.1%) | 12.94M -314.2K (-2.4%) | 1.56% -0.498 pp | 0.00% +0.000 pp | USD43.36 -53.0% | 23 qtrs — |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 591.7K +437.0K (+282.5%) | 12.05M +9.6M (+392.2%) | 1.46% +1.076 pp | 0.02% +0.016 pp | USD18.56 +9.7% | 3 qtrs — |
| 13 | GOLDMAN SACHS GROUP INC | 590.5K -735.0K (-55.4%) | 12.02M -8.9M (-42.7%) | 1.45% -1.810 pp | 0.00% -0.001 pp | USD22.53 -9.6% | 22 qtrs — |
| 14 | NANTAHALA CAPITAL MANAGEMENT, LLC | 360.4K -872.8K (-70.8%) | 7.34M -12.2M (-62.4%) | 0.89% -2.149 pp | 0.24% -0.435 pp | USD20.76 -1.9% | 23 qtrs — |
| 15 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 321.3K -13.8K (-4.1%) | 6.54M +1.2M (+23.4%) | 0.79% -0.034 pp | 0.02% +0.001 pp | USD13.14 +54.9% | 5 qtrs — |
| 16 | TWO SIGMA INVESTMENTS, LP | 318.4K +235.9K (+285.9%) | 6.48M +5.2M (+396.6%) | 0.78% +0.581 pp | 0.01% +0.007 pp | USD19.25 +5.8% | 9 qtrs — |
| 17 | HRT FINANCIAL LP | 260.9K +218.1K (+509.6%) | 5.31M +4.6M (+684.5%) | 0.64% +0.537 pp | 0.02% +0.014 pp | USD19.62 +3.8% | 6 qtrs — |
| 18 | WEISS ASSET MANAGEMENT LP | 254.1K +254.1K (+100.0%) | 5.17M +5.2M (+100.0%) | 0.63% +0.625 pp | 0.07% +0.072 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 19 | NORTHERN TRUST CORP | 250.6K -82.2K (-24.7%) | 5.10M -162.6K (-3.1%) | 0.62% -0.203 pp | 0.00% +0.000 pp | USD40.24 -49.4% | 23 qtrs — |
| 20 | MORGAN STANLEY | 230.5K -164.6K (-41.7%) | 4.69M -1.6M (-24.9%) | 0.57% -0.406 pp | 0.00% 0.000 pp | USD17.41 +16.9% | 23 qtrs — |
| 21 | MILLENNIUM MANAGEMENT LLC | 220.2K +166.9K (+312.8%) | 4.48M +3.6M (+431.3%) | 0.54% +0.411 pp | 0.00% +0.002 pp | USD20.43 -0.3% | 13 qtrs — |
| 22 | CITADEL ADVISORS LLC | 203.4K +156.6K (+334.6%) | 4.14M +3.4M (+459.3%) | 0.50% +0.386 pp | 0.00% +0.001 pp | USD18.98 +7.3% | 12 qtrs — |
| 23 | DEUTSCHE BANK AG\ | 195.3K +172.0K (+739.6%) | 3.98M +3.6M (+980.5%) | 0.48% +0.423 pp | 0.00% +0.001 pp | USD19.77 +3.0% | 23 qtrs — |
| 24 | ALGERT GLOBAL LLC | 193.6K +145.8K (+305.2%) | 3.94M +3.2M (+421.4%) | 0.48% +0.359 pp | 0.06% +0.049 pp | USD20.02 +1.7% | 12 qtrs — |
| 25 | MAN GROUP PLC | 190.2K -2.6K (-1.4%) | 3.87M +821.7K (+26.9%) | 0.47% -0.007 pp | 0.01% +0.001 pp | USD13.71 +48.5% | 4 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 186.8K -105.2K (-36.0%) | 3.80M -816.7K (-17.7%) | 0.46% -0.259 pp | 0.00% 0.000 pp | USD38.66 -47.3% | 23 qtrs — |
| 27 | AQR CAPITAL MANAGEMENT LLC | 180.5K -23.8K (-11.7%) | 3.68M +443.0K (+13.7%) | 0.44% -0.059 pp | 0.00% 0.000 pp | USD14.62 +39.3% | 4 qtrs — |
| 28 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 175.8K -41.7K (-19.2%) | 3.58M +138.4K (+4.0%) | 0.43% -0.103 pp | 0.00% +0.000 pp | USD14.15 +43.9% | 8 qtrs — |
| 29 | TWO SIGMA ADVISERS, LP | 171.8K +117.6K (+217.0%) | 3.50M +2.6M (+307.9%) | 0.42% +0.290 pp | 0.01% +0.005 pp | USD18.73 +8.7% | 8 qtrs — |
| 30 | JANE STREET GROUP, LLC | 162.0K -446.0 (-0.3%) | 3.30M +728.5K (+28.3%) | 0.40% -0.001 pp | 0.00% +0.000 pp | USD20.96 -2.9% | 12 qtrs — |
| 31 | JUMP FINANCIAL, LLC | 161.1K +161.1K (+100.0%) | 3.28M +3.3M (+100.0%) | 0.40% +0.397 pp | 0.04% +0.040 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 32 | NOMURA HOLDINGS INC | 156.8K +156.8K (+100.0%) | 3.19M +3.2M (+100.0%) | 0.39% +0.386 pp | 0.00% +0.004 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 33 | BESSEMER GROUP INC | 143.9K +143.9K (+100.0%) | 2.93M +2.9M (+100.0%) | 0.35% +0.354 pp | 0.00% +0.005 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 34 | AMERIPRISE FINANCIAL INC | 122.8K +2.4K (+2.0%) | 2.50M +595.5K (+31.3%) | 0.30% +0.006 pp | 0.00% +0.000 pp | USD13.92 +46.3% | 3 qtrs — |
| 35 | PANAGORA ASSET MANAGEMENT INC | 122.8K +92.4K (+303.2%) | 2.50M +2.0M (+418.9%) | 0.30% +0.227 pp | 0.01% +0.007 pp | USD19.23 +5.9% | 2 qtrs — |
| 36 | BANK OF NEW YORK MELLON CORP | 121.6K +10.7K (+9.6%) | 2.48M +721.3K (+41.1%) | 0.30% +0.026 pp | 0.00% +0.000 pp | USD37.76 -46.1% | 23 qtrs — |
| 37 | Y-INTERCEPT (HONG KONG) LTD | 117.4K +68.8K (+141.8%) | 2.39M +1.6M (+211.1%) | 0.29% +0.169 pp | 0.05% +0.035 pp | USD17.46 +16.6% | 9 qtrs — |
| 38 | PDT PARTNERS, LLC | 112.2K -220.6K (-66.3%) | 2.28M -3.0M (-56.6%) | 0.28% -0.543 pp | 0.15% -0.184 pp | USD10.73 +89.7% | 4 qtrs — |
| 39 | BANK OF AMERICA CORP /DE/ | 100.1K -126.0K (-55.7%) | 2.04M -1.5M (-43.0%) | 0.25% -0.310 pp | 0.00% 0.000 pp | USD27.86 -26.9% | 23 qtrs — |
| 40 | SG AMERICAS SECURITIES, LLC | 98.7K +92.2K (+1,420.6%) | 2.01M +1.9M (+1,851.5%) | 0.24% +0.227 pp | 0.00% +0.002 pp | USD20.06 +1.5% | 2 qtrs — |
| 41 | UBS GROUP AG | 97.1K -6.8K (-6.5%) | 1.98M +333.5K (+20.3%) | 0.24% -0.017 pp | 0.00% +0.000 pp | USD22.45 -9.3% | 23 qtrs — |
| 42 | RANGELEY CAPITAL, LLC | 96.8K -161.8K (-62.6%) | 1.97M -2.1M (-51.8%) | 0.24% -0.399 pp | 1.64% -1.903 pp | USD10.19 +99.8% | 4 qtrs — |
| 43 | INVESCO LTD. | 87.4K +12.4K (+16.6%) | 1.78M +593.9K (+50.1%) | 0.22% +0.031 pp | 0.00% +0.000 pp | USD21.46 -5.1% | 23 qtrs — |
| 44 | RBF CAPITAL, LLC | 81.7K -68.3K (-45.5%) | 1.66M -709.1K (-29.9%) | 0.20% -0.168 pp | 0.07% -0.032 pp | USD10.19 +99.8% | 4 qtrs — |
| 45 | RUSSELL INVESTMENTS GROUP, LTD. | 80.8K -12.3K (-13.2%) | 1.64M +172.7K (+11.7%) | 0.20% -0.030 pp | 0.00% +0.000 pp | USD16.90 +20.5% | 14 qtrs — |
| 46 | BARCLAYS PLC | 74.7K +14.7K (+24.5%) | 1.52M -2.0M (-56.3%) | 0.18% +0.036 pp | 0.00% -0.001 pp | USD23.33 -12.7% | 16 qtrs — |
| 47 | NUVEEN, LLC | 63.1K -12.8K (-16.8%) | 1.28M +84.6K (+7.1%) | 0.16% -0.032 pp | 0.00% +0.000 pp | USD10.19 +99.8% | 4 qtrs — |
| 48 | ENGINEERS GATE MANAGER LP | 62.4K +36.0K (+136.5%) | 1.27M +852.7K (+204.4%) | 0.15% +0.089 pp | 0.02% +0.010 pp | USD21.50 -5.3% | 8 qtrs — |
| 49 | EMPOWERED FUNDS, LLC | 60.1K +60.1K (+100.0%) | 1.22M +1.2M (+100.0%) | 0.15% +0.148 pp | 0.01% +0.010 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 50 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 60.1K +60.1K (+100.0%) | 1.22M +1.2M (+100.0%) | 0.15% +0.148 pp | 0.03% +0.026 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 51 | DIMENSIONAL FUND ADVISORS LP | 58.0K +22.1K (+61.3%) | 1.18M +612.1K (+107.6%) | 0.14% +0.054 pp | 0.00% +0.000 pp | USD29.06 -29.9% | 11 qtrs — |
| 52 | GSA CAPITAL PARTNERS LLP | 51.3K +26.0K (+102.9%) | 1.05M +645.0K (+161.3%) | 0.13% +0.064 pp | 0.09% +0.057 pp | USD16.91 +20.4% | 5 qtrs — |
| 53 | MACKENZIE FINANCIAL CORP | 51.4K -5.4K (-9.5%) | 1.04M +141.5K (+15.8%) | 0.13% -0.013 pp | 0.00% +0.000 pp | USD13.48 +51.0% | 3 qtrs — |
| 54 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 50.3K +8.9K (+21.4%) | 1.02M +368.8K (+56.2%) | 0.12% +0.022 pp | 0.00% +0.001 pp | USD15.34 +32.7% | 3 qtrs — |
| 55 | RHUMBLINE ADVISERS | 44.2K -6.2K (-12.4%) | 900.6K +102.1K (+12.8%) | 0.11% -0.015 pp | 0.00% +0.000 pp | USD39.07 -47.9% | 23 qtrs — |
| 56 | CANADA PENSION PLAN INVESTMENT BOARD | 44.1K -183.2K (-80.6%) | 897.9K -2.7M (-75.0%) | 0.11% -0.451 pp | 0.00% -0.002 pp | USD13.35 +52.5% | 3 qtrs — |
| 57 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 43.7K +43.7K (+100.0%) | 889.6K +889.6K (+100.0%) | 0.11% +0.108 pp | 0.00% +0.000 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 58 | HUSSMAN STRATEGIC ADVISORS, INC. | 42.0K +42.0K (+100.0%) | 855.1K +855.1K (+100.0%) | 0.10% +0.103 pp | 0.21% +0.207 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 59 | MARTINGALE ASSET MANAGEMENT L P | 39.4K +202.0 (+0.5%) | 801.8K +182.0K (+29.4%) | 0.10% +0.001 pp | 0.02% +0.005 pp | USD14.97 +36.0% | 3 qtrs — |
| 60 | POINT72 ASSET MANAGEMENT, L.P. | 38.8K +38.8K (+100.0%) | 790.9K +790.9K (+100.0%) | 0.10% +0.096 pp | 0.00% +0.001 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 61 | AMERICAN CENTURY COMPANIES INC | 36.6K -2.5K (-6.4%) | 746.0K +126.4K (+20.4%) | 0.09% -0.006 pp | 0.00% +0.000 pp | USD15.82 +28.7% | 2 qtrs — |
| 62 | FMR LLC | 35.6K -64.9K (-64.6%) | 724.8K -865.6K (-54.4%) | 0.09% -0.160 pp | 0.00% +0.000 pp | USD45.66 -55.4% | 23 qtrs — |
| 63 | WELLS FARGO & COMPANY/MN | 32.8K +6.9K (+26.5%) | 667.0K +257.5K (+62.9%) | 0.08% +0.017 pp | 0.00% +0.000 pp | USD27.49 -25.9% | 17 qtrs — |
| 64 | QUEST PARTNERS LLC | 32.1K +16.8K (+110.4%) | 653.4K +412.1K (+170.8%) | 0.08% +0.041 pp | 0.04% +0.021 pp | USD16.96 +20.0% | 9 qtrs — |
| 65 | CAMBRIA INVESTMENT MANAGEMENT, L.P. | 31.3K +31.3K (+100.0%) | 637.5K +637.5K (+100.0%) | 0.08% +0.077 pp | 0.04% +0.037 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 66 | ALLIANCEBERNSTEIN L.P. | 30.9K +3.1K (+11.0%) | 628.3K +188.4K (+42.8%) | 0.08% +0.008 pp | 0.00% +0.000 pp | USD51.75 -60.7% | 23 qtrs — |
| 67 | RAFFERTY ASSET MANAGEMENT, LLC | 30.3K -13.8K (-31.3%) | 616.5K -80.6K (-11.6%) | 0.07% -0.034 pp | 0.00% 0.000 pp | USD45.35 -55.1% | 21 qtrs — |
| 68 | PRICE T ROWE ASSOCIATES INC /MD/ | 29.7K -20.3K (-40.6%) | 605.0K -186.0K (-23.5%) | 0.07% -0.050 pp | 0.00% +0.000 pp | USD45.39 -55.1% | 17 qtrs — |
| 69 | CAPTION MANAGEMENT, LLC | 29.5K -6.6K (-18.2%) | 600.6K +29.9K (+5.2%) | 0.07% -0.016 pp | 0.00% 0.000 pp | USD13.42 +51.7% | 5 qtrs — |
| 70 | STRS OHIO | 29.3K +1.1K (+3.9%) | 596.5K +150.4K (+33.7%) | 0.07% +0.003 pp | 0.00% +0.001 pp | USD15.20 +33.9% | 3 qtrs — |
| 71 | TUDOR INVESTMENT CORP ET AL | 28.3K +8.8K (+45.0%) | 576.3K +267.4K (+86.6%) | 0.07% +0.022 pp | 0.00% +0.001 pp | USD17.23 +18.2% | 9 qtrs — |
| 72 | FRANKLIN RESOURCES INC | 27.6K -60.2K (-68.6%) | 561.6K -826.8K (-59.6%) | 0.07% -0.148 pp | 0.00% 0.000 pp | USD24.06 -15.4% | 21 qtrs — |
| 73 | FOX RUN MANAGEMENT, L.L.C. | 25.7K +25.7K (+100.0%) | 522.8K +522.8K (+100.0%) | 0.06% +0.063 pp | 0.08% +0.081 pp | USD20.36 +0.0% | 6 qtrs — |
| 74 | LOS ANGELES CAPITAL MANAGEMENT LLC | 33.8K -3.2K (-8.7%) | 507.6K -77.8K (-13.3%) | 0.08% -0.008 pp | 0.00% 0.000 pp | USD13.35 +52.5% | 3 qtrs — |
| 75 | SKOPOS LABS, INC. | 23.8K +3.0K (+14.3%) | 490.0K +161.3K (+49.1%) | 0.06% +0.007 pp | 0.02% -0.013 pp | USD16.38 +24.3% | 3 qtrs — |
| 76 | CREATIVE PLANNING | 23.1K -3.4K (-13.0%) | 470.9K +50.6K (+12.0%) | 0.06% -0.009 pp | 0.00% +0.000 pp | USD11.51 +76.9% | 4 qtrs — |
| 77 | LSV ASSET MANAGEMENT | 23.1K +23.1K (+100.0%) | 470.0K +470.0K (+100.0%) | 0.06% +0.057 pp | 0.00% +0.001 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 78 | WINTON GROUP LTD | 21.6K +21.6K (+100.0%) | 439.6K +439.6K (+100.0%) | 0.05% +0.053 pp | 0.02% +0.015 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 79 | OXFORD ASSET MANAGEMENT LLP | 21.5K +21.5K (+100.0%) | 437.9K +437.9K (+100.0%) | 0.05% +0.053 pp | 0.18% +0.178 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 80 | QUANTINNO CAPITAL MANAGEMENT LP | 21.1K -11.0 (-0.1%) | 430.0K +95.7K (+28.6%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD15.82 +28.7% | 2 qtrs — |
| 81 | STATE OF WISCONSIN INVESTMENT BOARD | 19.8K -2.4K (-10.7%) | 403.8K +52.3K (+14.9%) | 0.05% -0.006 pp | 0.00% +0.000 pp | USD13.35 +52.5% | 23 qtrs — |
| 82 | QUANTEDGE CAPITAL PTE LTD | 19.3K +19.3K (+100.0%) | 392.8K +392.8K (+100.0%) | 0.05% +0.048 pp | 0.19% +0.187 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 83 | ADAR1 CAPITAL MANAGEMENT, LLC | 18.9K -5.4M (-99.7%) | 383.8K -84.9M (-99.5%) | 0.05% -13.223 pp | 0.03% -7.981 pp | USD12.61 +61.5% | 9 qtrs — |
| 84 | PENSERRA CAPITAL MANAGEMENT LLC | 18.8K +18.8K (+100.0%) | 383.0K +383.0K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.005 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 85 | JPMORGAN CHASE & CO | 18.6K -153.3K (-89.2%) | 379.5K -2.3M (-86.0%) | 0.05% -0.378 pp | 0.00% 0.000 pp | USD14.47 +40.7% | 23 qtrs — |
| 86 | ENTROPY TECHNOLOGIES, LP | 17.9K +17.9K (+100.0%) | 364.3K +364.3K (+100.0%) | 0.04% +0.044 pp | 0.02% +0.020 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 87 | CAMPBELL & CO INVESTMENT ADVISER LLC | 17.6K +17.6K (+100.0%) | 358.9K +358.9K (+100.0%) | 0.04% +0.043 pp | 0.02% +0.017 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 88 | POLYMER CAPITAL MANAGEMENT (US) LLC | 17.5K +6.3K (+56.9%) | 356.2K +179.8K (+102.0%) | 0.04% +0.016 pp | 0.04% +0.019 pp | USD15.04 +35.4% | 4 qtrs — |
| 89 | INTEGRATED QUANTITATIVE INVESTMENTS LLC | 17.0K +17.0K (+100.0%) | 345.6K +345.6K (+100.0%) | 0.04% +0.042 pp | 0.07% +0.074 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 90 | LEGATO CAPITAL MANAGEMENT LLC | 17.0K +17.0K (+100.0%) | 345.6K +345.6K (+100.0%) | 0.04% +0.042 pp | 0.03% +0.030 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 91 | METLIFE INVESTMENT MANAGEMENT, LLC | 16.7K -3.1K (-15.5%) | 339.6K +27.2K (+8.7%) | 0.04% -0.008 pp | 0.00% +0.000 pp | USD43.91 -53.6% | 23 qtrs — |
| 92 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 15.3K -2.8K (-15.6%) | 311.7K +24.4K (+8.5%) | 0.04% -0.007 pp | 0.00% +0.000 pp | USD15.82 +28.7% | 7 qtrs — |
| 93 | MARINER, LLC | 15.2K -497.0 (-3.2%) | 309.7K +61.2K (+24.6%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD15.82 +28.7% | 2 qtrs — |
| 94 | EJF CAPITAL LLC | 15.0K +15.0K (+100.0%) | 305.4K +305.4K (+100.0%) | 0.04% +0.037 pp | 0.17% +0.173 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 95 | ABACUS WEALTH PARTNERS, LLC | 14.1K +14.1K (+100.0%) | 287.3K +287.3K (+100.0%) | 0.03% +0.035 pp | 0.03% +0.028 pp | USD20.36 +0.0% | 1 qtrs NEW |
| 96 | PRELUDE CAPITAL MANAGEMENT, LLC | 13.6K +13.6K (+100.0%) | 277.7K +277.7K (+100.0%) | 0.03% +0.034 pp | 0.02% +0.020 pp | USD20.36 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 75 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.11% | 178.4K | 0.51% |
| 2 | EA Bridgeway Omni Small-Cap Value ETF BSVO | 0.06% | 1.06M | 0.47% |
| 3 | WisdomTree U.S. SmallCap Fund EES | 0.05% | 356.1K | 0.38% |
| 4 | iShares Micro-Cap ETF IWC | 0.05% | 731.5K | 0.60% |
| 5 | Vanguard U.S. Multifactor ETF VFMF | 0.03% | 186.1K | 0.18% |
| 6 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.03% | 75.8K | 0.39% |
| 7 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 253.0K | 0.20% |
| 8 | Vanguard U.S. Momentum Factor ETF VFMO | 0.02% | 407.8K | 0.13% |
| 9 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.02% | 637.3K | 0.34% |
| 10 | Vanguard Russell 2000 Value ETF VTWV | 0.02% | 273.0K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
1.02
Neutral
Buys
2
Sells
1
Shares acquired
56.0K
Shares disposed
55.0K
Cash buys
1.00
Cash sales
—
Net activity
+1,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 1,000 | 11.70 | 11.7K | 8,450 | D | ↗ |
| 2026-04-02 | Seehra Jasbir | Director / Officer | M-Exempt | A | Common Stock | 55,000 | 0.30 | 16.5K | 440,708 | D | ↗ |
| 2026-03-09 | Newton Charles W. | Director | A-Award | A | Stock Option (Right to Buy) | 14,788 | 11.35 | 167.8K | 14,788 | D | ↗ |
| 2026-03-09 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 2,000 | 11.21 | 22.4K | 7,450 | D | ↗ |
| 2026-02-24 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 217,000 | 15.52 | 3.37M | 217,000 | D | ↗ |
| 2026-02-24 | Regnante Keith | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,000 | 15.52 | 931.2K | 60,000 | D | ↗ |
| 2026-02-24 | Cho Esther | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 80,000 | 15.52 | 1.24M | 80,000 | D | ↗ |
| 2026-02-19 | Seehra Jasbir | Director / Officer | S-Sale | D | Common Stock | 7,015 | 16.17 | 113.4K | 385,708 | D | ↗ |
| 2026-02-18 | Regnante Keith | Officer | S-Sale | D | Common Stock | 4,739 | 16.35 | 77.5K | 39,261 | D | ↗ |
| 2026-02-18 | Lerner Lorena Raquel | Officer | S-Sale | D | Common Stock | 3,873 | 16.35 | 63.3K | 31,127 | D | ↗ |
| 2026-02-18 | Cho Esther | Officer | S-Sale | D | Common Stock | 4,745 | 16.35 | 77.6K | 39,755 | D | ↗ |
| 2026-01-07 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 62,500 | 63.61 | 3.98M | 62,500 | D | ↗ |
| 2025-11-21 | ORBIMED ADVISORS LLC | Director | D-Return | D | Common Stock | 140,057 | 17.75 | 2.49M | 759,155 | I | ↗ |
| 2025-11-21 | Knowles Julius | Director | D-Return | D | Common Stock | 191,527 | 17.75 | 3.40M | 150,047 | I | ↗ |
| 2025-11-21 | GORDON CARL L | Director | D-Return | D | Common Stock | 140,057 | 17.75 | 2.49M | 759,155 | I | ↗ |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | S-Sale | D | Common Stock, $0.0001 par value per share | 155,262 | 17.75 | 2.76M | 0 | I | ↗ |
| 2025-10-15 | ADAR1 Capital Management, LLC | 10% Owner | S-Sale | D | Common Stock | 743,358 | 17.75 | 13.19M | 0 | I | ↗ |
| 2025-09-03 | Seehra Jasbir | Director / Officer | A-Award | A | Common Stock | 90,500 | 0.00 | — | 392,723 | D | ↗ |
| 2025-08-06 | Lerner Lorena Raquel | Officer | — | — | Employee Stock Option (Right to Buy) | 23,000 | 56.18 | 1.29M | 0 | D | ↗ |
| 2025-08-06 | Cho Esther | Officer | — | — | Employee Stock Option (Right to Buy) | 25,000 | 46.30 | 1.16M | 0 | D | ↗ |
| 2025-06-20 | ADAR1 Capital Management, LLC | 10% Owner | X-InTheMoney | D | Common Stock | 200 | 70.00 | 14.0K | 743,358 | I | ↗ |
| 2025-06-04 | Seth Alpna | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | D | ↗ |
| 2025-06-04 | Nussbaum Ran | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 10,500 | 14.82 | 155.6K | 10,500 | D | ↗ |
| 2025-06-04 | Knowles Julius | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 6,441 | D | ↗ |
| 2025-06-04 | Kariv Tomer | Director / 10% Owner | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | D | ↗ |
| 2025-06-04 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 14.82 | 155.6K | 10,500 | D | ↗ |
| 2025-06-04 | GORDON CARL L | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | D | ↗ |
| 2025-06-04 | Farzan Nima | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | D | ↗ |
| 2025-06-04 | BIENAIME JEAN JACQUES | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 14.82 | 155.6K | 10,500 | D | ↗ |
| 2025-05-16 | ADAR1 Capital Management, LLC | 10% Owner | E-ExpireShort | D | Put Option (obligation to buy) | 178 | 10.00 | 1.8K | 0 | I | ↗ |
| 2025-04-09 | ADAR1 Capital Management, LLC | 10% Owner | P-Purchase | A | Common Stock | 18,560 | 9.40 | 174.4K | 3,493,404 | I | ↗ |
| 2025-04-08 | ADAR1 Capital Management, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 3,474,844 | I | ↗ |
| 2025-04-04 | Seehra Jasbir | Director / Officer | M-Exempt | A | Common Stock | 49,367 | 0.30 | 14.8K | 302,223 | D | ↗ |
| 2025-04-03 | ADAR1 Capital Management, LLC | 10% Owner | — | — | Put Option (obligation to buy) | 17,800 | 10.00 | 178.0K | 0 | I | ↗ |
| 2025-02-18 | Rovaldi Christopher | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 60,000 | D | ↗ |
| 2025-02-18 | Regnante Keith | Officer | A-Award | A | Common Stock | 44,000 | 0.00 | — | 44,000 | D | ↗ |
| 2025-02-18 | CHYUNG YUNG H. | Officer | A-Award | A | Common Stock | 44,000 | 0.00 | — | 44,000 | D | ↗ |
| 2024-11-08 | CHYUNG YUNG H. | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,000 | 67.91 | 7.47M | 110,000 | D | ↗ |
| 2024-11-01 | CHYUNG YUNG H. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-02 | ADAR1 Capital Management, LLC | 10% Owner | — | — | Put Option (right to sell) | 100 | 60.00 | 6.0K | 0 | I | ↗ |
| 2024-10-01 | ADAR1 Capital Management, LLC | 10% Owner | — | — | Put Option (right to sell) | 200 | 70.00 | 14.0K | 0 | I | ↗ |
| 2024-08-13 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 29,400 | 44.01 | 1.29M | 119,522 | — | ↗ |
| 2024-08-13 | GORDON CARL L | Director | S-Sale | D | Common Stock | 220,600 | 44.01 | 9.71M | 899,212 | — | ↗ |
| 2024-06-03 | BIENAIME JEAN JACQUES | Director | A-Award | A | Stock Option (right to buy) | 17,600 | 48.67 | 856.6K | 17,600 | — | ↗ |
| 2024-06-01 | BIENAIME JEAN JACQUES | Director | — | D | Common Stock | 0 | 0.00 | — | 200 | — | ↗ |
| 2024-05-30 | Seth Alpna | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 46.31 | 463.1K | 10,000 | — | ↗ |
| 2024-05-30 | Nussbaum Ran | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 10,000 | 46.31 | 463.1K | 10,000 | — | ↗ |
| 2024-05-30 | Knowles Julius | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 46.31 | 463.1K | 10,000 | — | ↗ |
| 2024-05-30 | Kariv Tomer | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 10,000 | 46.31 | 463.1K | 10,000 | — | ↗ |
| 2024-05-30 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 46.31 | 463.1K | 10,000 | — | ↗ |
| 2024-05-30 | GORDON CARL L | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 46.31 | 463.1K | 10,000 | — | ↗ |
| 2024-05-30 | Farzan Nima | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 46.31 | 463.1K | 10,000 | — | ↗ |
| 2024-02-23 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 63.61 | 7.95M | 125,000 | — | ↗ |
| 2024-02-13 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 56.18 | 7.02M | 125,000 | — | ↗ |
| 2024-02-13 | Rovaldi Christopher | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 56.18 | 8.43M | 150,000 | — | ↗ |
| 2024-02-13 | Regnante Keith | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 56.18 | 2.25M | 40,000 | — | ↗ |
| 2024-02-13 | Cooper Simon Peter | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 56.18 | 2.25M | 40,000 | — | ↗ |
| 2024-01-04 | Regnante Keith | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 40,000 | 16.00 | 640.0K | 53,622 | — | ↗ |
| 2023-11-04 | Regnante Keith | Officer | M-Exempt | A | Common Stock | 40,000 | 16.00 | 640.0K | 40,000 | — | ↗ |
| 2023-06-09 | Regnante Keith | Officer | S-Sale | D | Common Stock | 1,428 | 46.46 | 66.3K | 2,579 | — | ↗ |
| 2023-06-08 | Regnante Keith | Officer | S-Sale | D | Common Stock | 2,699 | 48.65 | 131.3K | 0 | — | ↗ |
| 2023-06-06 | Seth Alpna | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 48.79 | 487.9K | 10,000 | — | ↗ |
| 2023-06-06 | Nussbaum Ran | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 10,000 | 48.79 | 487.9K | 10,000 | — | ↗ |
| 2023-06-06 | Knowles Julius | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 48.79 | 487.9K | 10,000 | — | ↗ |
| 2023-06-06 | Kariv Tomer | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 10,000 | 48.79 | 487.9K | 10,000 | — | ↗ |
| 2023-06-06 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 48.79 | 487.9K | 10,000 | — | ↗ |
| 2023-06-06 | GORDON CARL L | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 48.79 | 487.9K | 10,000 | — | ↗ |
| 2023-06-06 | Farzan Nima | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 48.79 | 487.9K | 10,000 | — | ↗ |
| 2023-05-01 | Seth Alpna | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 46.07 | 921.4K | 20,000 | — | ↗ |
| 2023-04-08 | Seehra Jasbir | Director / Officer | M-Exempt | A | Common Stock | 4,000 | 0.48 | 1.9K | 252,856 | — | ↗ |
| 2023-02-16 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 54.38 | 10.88M | 200,000 | — | ↗ |
| 2023-02-16 | Rovaldi Christopher | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 54.38 | 5.44M | 100,000 | — | ↗ |
| 2023-02-16 | Regnante Keith | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 54.38 | 2.18M | 40,000 | — | ↗ |
| 2023-02-16 | Cooper Simon Peter | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 54.38 | 2.18M | 40,000 | — | ↗ |
| 2022-11-29 | Pontifax Management 4 G.P. (2015) Ltd. | Director | X-InTheMoney | D | Call Options (obligation to sell) | 1,914 | 0.00 | — | 0 | — | ↗ |
| 2022-11-29 | Nussbaum Ran | Director | X-InTheMoney | D | Common Stock | 1,914 | 0.00 | 0.19 | 1,226,412 | — | ↗ |
| 2022-11-29 | Kariv Tomer | Director | X-InTheMoney | D | Common Stock | 3,539 | 0.00 | 0.35 | 2,284,612 | — | ↗ |
| 2022-07-15 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 46,034 | 30.00 | 1.38M | 95,100 | — | ↗ |
| 2022-07-13 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 1,916 | 30.00 | 57.5K | 95,100 | — | ↗ |
| 2022-06-14 | Lachey Jennifer | Officer | M-Exempt | A | Common Stock | 9,400 | 0.30 | 2.8K | 95,100 | — | ↗ |
| 2022-06-09 | Seehra Jasbir | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,000 | 0.00 | — | 8,822 | — | ↗ |
| 2022-06-01 | Nussbaum Ran | Director | A-Award | A | Stock Options (right to buy) | 8,293 | 0.00 | — | 8,293 | — | ↗ |
| 2022-06-01 | Knowles Julius | Director | A-Award | A | Stock Options (right to buy) | 8,293 | 0.00 | — | 8,293 | — | ↗ |
| 2022-06-01 | Kariv Tomer | Director / 10% Owner | A-Award | A | Stock Options (right to buy) | 8,293 | 32.95 | 273.3K | 8,293 | — | ↗ |
| 2022-06-01 | GRAY MARY ANN | Director | A-Award | A | Stock Options (right to buy) | 8,293 | 0.00 | — | 8,293 | — | ↗ |
| 2022-06-01 | GORDON CARL L | Director | A-Award | A | Stock Options (right to buy) | 8,293 | 0.00 | — | 8,293 | — | ↗ |
| 2022-06-01 | Farzan Nima | Director | A-Award | A | Stock Options (right to buy) | 8,293 | 0.00 | — | 8,293 | — | ↗ |
| 2022-05-11 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 944 | 42.49 | 40.1K | 86,658 | — | ↗ |
| 2022-04-11 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 559 | 64.15 | 35.9K | 85,700 | — | ↗ |
| 2022-04-06 | Rovaldi Christopher | Officer | M-Exempt | A | Common Stock | 1,728 | 16.00 | 27.6K | 1,728 | — | ↗ |
| 2022-04-04 | Lachey Jennifer | Officer | M-Exempt | A | Common Stock | 7,950 | 0.30 | 2.4K | 93,650 | — | ↗ |
| 2022-04-01 | Rovaldi Christopher | Officer | S-Sale | D | Common Stock | 287 | 56.89 | 16.3K | 471 | — | ↗ |
| 2022-03-11 | Lachey Jennifer | Officer | M-Exempt | A | Common Stock | 2,650 | 0.30 | 795.00 | 88,350 | — | ↗ |
| 2022-02-11 | Lachey Jennifer | Officer | M-Exempt | A | Common Stock | 2,650 | 0.30 | 795.00 | 88,350 | — | ↗ |
| 2022-02-01 | Rovaldi Christopher | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 49.34 | 4.93M | 100,000 | — | ↗ |
| 2022-01-21 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 165,000 | 46.30 | 7.64M | 165,000 | — | ↗ |
| 2022-01-21 | Regnante Keith | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 46.30 | 2.32M | 50,000 | — | ↗ |
| 2022-01-21 | Lachey Jennifer | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 46.30 | 2.32M | 50,000 | — | ↗ |
| 2022-01-21 | Cooper Simon Peter | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 46.30 | 2.32M | 50,000 | — | ↗ |
| 2022-01-11 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 2,650 | 0.30 | 795.00 | 89,955 | — | ↗ |
| 2022-01-05 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 2,650 | 60.00 | 159.0K | 85,700 | — | ↗ |
| 2022-01-05 | Knowles Julius | Director | S-Sale | D | Common Stock | 435 | 59.00 | 25.7K | 232,727 | — | ↗ |
| 2022-01-04 | Knowles Julius | Director | S-Sale | D | Common Stock | 2,195 | 58.86 | 129.2K | 234,319 | — | ↗ |
| 2022-01-03 | Knowles Julius | Director | S-Sale | D | Common Stock | 162 | 59.40 | 9.6K | 242,238 | — | ↗ |
| 2021-12-15 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 735 | 0.30 | 220.50 | 95,255 | — | ↗ |
| 2021-12-13 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,915 | 0.30 | 574.50 | 95,990 | — | ↗ |
| 2021-12-02 | Knowles Julius | Director | S-Sale | D | Common Stock | 90 | 54.67 | 4.9K | 251,536 | — | ↗ |
| 2021-12-01 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,566 | 56.27 | 88.1K | 385,752 | — | ↗ |
| 2021-11-11 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 4,561 | 59.78 | 272.7K | 85,700 | — | ↗ |
| 2021-11-10 | Lachey Jennifer | Officer | M-Exempt | A | Common Stock | 15,900 | 0.30 | 4.8K | 101,600 | — | ↗ |
| 2021-11-04 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 10,600 | 0.30 | 3.2K | 119,105 | — | ↗ |
| 2021-11-03 | Knowles Julius | Director | S-Sale | D | Common Stock | 3,597 | 42.45 | 152.7K | 399,257 | — | ↗ |
| 2021-11-02 | Knowles Julius | Director | S-Sale | D | Common Stock | 991 | 43.04 | 42.7K | 276,649 | — | ↗ |
| 2021-11-01 | Knowles Julius | Director | S-Sale | D | Common Stock | 4,599 | 41.85 | 192.5K | 284,557 | — | ↗ |
| 2021-10-20 | Knowles Julius | Director | S-Sale | D | Common Stock | 229 | 37.55 | 8.6K | 430,340 | — | ↗ |
| 2021-10-19 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,323 | 38.05 | 50.3K | 291,227 | — | ↗ |
| 2021-10-18 | Knowles Julius | Director | S-Sale | D | Common Stock | 92 | 38.46 | 3.5K | 433,302 | — | ↗ |
| 2021-10-15 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,199 | 39.44 | 47.3K | 298,052 | — | ↗ |
| 2021-10-14 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,730 | 40.13 | 69.4K | 301,228 | — | ↗ |
| 2021-10-05 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,584 | 40.03 | 63.4K | 449,261 | — | ↗ |
| 2021-10-04 | Knowles Julius | Director | S-Sale | D | Common Stock | 2,267 | 40.06 | 90.8K | 450,845 | — | ↗ |
| 2021-10-01 | Knowles Julius | Director | S-Sale | D | Common Stock | 3,827 | 40.16 | 153.7K | 453,112 | — | ↗ |
| 2021-09-27 | Knowles Julius | Director | S-Sale | D | Common Stock | 17,854 | 40.51 | 723.3K | 327,731 | — | ↗ |
| 2021-08-17 | Lachey Jennifer | Officer | M-Exempt | A | Common Stock | 1,293 | 0.30 | 387.90 | 85,700 | — | ↗ |
| 2021-08-10 | Cooper Simon Peter | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 34.98 | 2.10M | 60,000 | — | ↗ |
| 2021-08-02 | Cooper Simon Peter | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-02 | Knowles Julius | Director | S-Sale | D | Common Stock | 3,776 | 41.72 | 157.5K | 345,585 | — | ↗ |
| 2021-07-01 | Knowles Julius | Director | S-Sale | D | Common Stock | 728 | 41.89 | 30.5K | 355,017 | — | ↗ |
| 2021-06-24 | Lachey Jennifer | Officer | M-Exempt | A | Common Stock | 6,500 | 0.30 | 2.0K | 84,407 | — | ↗ |
| 2021-06-11 | Ordonez Claudia | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,000 | 0.48 | 480.00 | 98,211 | — | ↗ |
| 2021-06-11 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 219 | 52.13 | 11.4K | 77,907 | — | ↗ |
| 2021-06-07 | Knowles Julius | Director | S-Sale | D | Common Stock | 858 | 51.46 | 44.2K | 543,464 | — | ↗ |
| 2021-06-04 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,950 | 47.23 | 92.1K | 370,109 | — | ↗ |
| 2021-06-03 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,903 | 48.15 | 91.6K | 372,059 | — | ↗ |
| 2021-06-02 | Knowles Julius | Director | S-Sale | D | Common Stock | 4,944 | 48.35 | 239.0K | 562,028 | — | ↗ |
| 2021-06-01 | Nussbaum Ran | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,293 | 51.48 | 426.9K | 8,293 | — | ↗ |
| 2021-06-01 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,504 | 51.90 | 78.1K | 381,701 | — | ↗ |
| 2021-06-01 | Kariv Tomer | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,293 | 51.48 | 426.9K | 8,293 | — | ↗ |
| 2021-06-01 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 8,293 | 51.48 | 426.9K | 8,293 | — | ↗ |
| 2021-06-01 | GORDON CARL L | Director | A-Award | A | Stock Option (right to buy) | 8,293 | 51.48 | 426.9K | 8,293 | — | ↗ |
| 2021-06-01 | Farzan Nima | Director | A-Award | A | Stock Option (right to buy) | 8,293 | 51.48 | 426.9K | 8,293 | — | ↗ |
| 2021-05-13 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 6,220 | 0.11 | 684.20 | 0 | — | ↗ |
| 2021-05-11 | Ordonez Claudia | Officer | S-Sale | D | Common Stock | 1,000 | 50.15 | 50.2K | 0 | — | ↗ |
| 2021-05-11 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 2,650 | 0.30 | 795.00 | 132,355 | — | ↗ |
| 2021-05-04 | Knowles Julius | Director | S-Sale | D | Common Stock | 339 | 54.35 | 18.4K | 383,205 | — | ↗ |
| 2021-05-03 | Knowles Julius | Director | S-Sale | D | Common Stock | 3,509 | 56.04 | 196.6K | 398,506 | — | ↗ |
| 2021-04-12 | Ordonez Claudia | Officer | S-Sale | D | Common Stock | 367 | 60.01 | 22.0K | 233 | — | ↗ |
| 2021-04-12 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,300 | 0.30 | 1.6K | 135,005 | — | ↗ |
| 2021-04-06 | Knowles Julius | Director | S-Sale | D | Common Stock | 54 | 59.95 | 3.2K | 601,146 | — | ↗ |
| 2021-04-05 | Knowles Julius | Director | S-Sale | D | Common Stock | 6,972 | 60.26 | 420.1K | 405,685 | — | ↗ |
| 2021-04-01 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 9,996 | 0.11 | 1.1K | 0 | — | ↗ |
| 2021-04-01 | Knowles Julius | Director | S-Sale | D | Common Stock | 283 | 60.82 | 17.2K | 416,537 | — | ↗ |
| 2021-03-11 | Ordonez Claudia | Officer | S-Sale | D | Common Stock | 605 | 64.86 | 39.2K | 0 | — | ↗ |
| 2021-03-11 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,300 | 0.30 | 1.6K | 140,305 | — | ↗ |
| 2021-03-04 | Knowles Julius | Director | S-Sale | D | Common Stock | 126 | 58.03 | 7.3K | 420,825 | — | ↗ |
| 2021-03-03 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,894 | 57.79 | 109.5K | 425,913 | — | ↗ |
| 2021-03-02 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,095 | 58.90 | 64.5K | 646,232 | — | ↗ |
| 2021-03-01 | Knowles Julius | Director | S-Sale | D | Common Stock | 792 | 66.04 | 52.3K | 651,017 | — | ↗ |
| 2021-02-26 | Lachey Jennifer | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 33,200 | 0.11 | 3.7K | 9,996 | — | ↗ |
| 2021-02-18 | Knowles Julius | Director | S-Sale | D | Common Stock | 552 | 64.17 | 35.4K | 439,709 | — | ↗ |
| 2021-02-17 | Knowles Julius | Director | S-Sale | D | Common Stock | 421 | 58.74 | 24.7K | 446,715 | — | ↗ |
| 2021-02-16 | Knowles Julius | Director | S-Sale | D | Common Stock | 661 | 59.34 | 39.2K | 449,835 | — | ↗ |
| 2021-02-12 | Knowles Julius | Director | S-Sale | D | Common Stock | 1,397 | 61.03 | 85.3K | 677,993 | — | ↗ |
| 2021-02-11 | Ordonez Claudia | Officer | M-Exempt | A | Common Stock | 1,000 | 0.48 | 480.00 | 1,000 | — | ↗ |
| 2021-02-11 | Lachey Jennifer | Officer | S-Sale | D | Common Stock | 14 | 68.05 | 952.70 | 27,991 | — | ↗ |
| 2021-02-11 | Knowles Julius | Director | S-Sale | D | Common Stock | 35 | 67.98 | 2.4K | 453,878 | — | ↗ |
| 2021-01-10 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 127,200 | 70.93 | 9.02M | 127,200 | — | ↗ |
| 2021-01-10 | Regnante Keith | Officer | A-Award | A | Employee Stock Option (right to buy) | 49,150 | 70.93 | 3.49M | 49,150 | — | ↗ |
| 2021-01-10 | Ordonez Claudia | Officer | A-Award | A | Employee Stock Option (right to buy) | 42,250 | 70.93 | 3.00M | 42,250 | — | ↗ |
| 2021-01-10 | Lachey Jennifer | Officer | A-Award | A | Employee Stock Option (right to buy) | 42,250 | 70.93 | 3.00M | 42,250 | — | ↗ |
| 2020-12-17 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 16,587 | 82.74 | 1.37M | 16,587 | — | ↗ |
| 2020-11-17 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | P-Purchase | A | Common Stock | 26,634 | 50.00 | 1.33M | 2,288,151 | — | ↗ |
| 2020-11-17 | Nussbaum Ran | Director / 10% Owner | P-Purchase | A | Common Stock | 26,634 | 50.00 | 1.33M | 2,288,151 | — | ↗ |
| 2020-11-17 | Kariv Tomer | Director / 10% Owner | P-Purchase | A | Common Stock | 12,966 | 50.00 | 648.3K | 1,122,768 | — | ↗ |
| 2020-05-29 | Farzan Nima | Director | A-Award | A | Stock Option (right to buy) | 8,500 | 28.74 | 244.3K | 8,500 | — | ↗ |
| 2020-04-13 | Seehra Jasbir | Director / Officer | C-Conversion | A | Common Stock | 11,169 | 0.00 | — | 223,856 | — | ↗ |
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | C-Conversion | A | Common Stock | 79,653 | 0.00 | — | 1,108,926 | — | ↗ |
| 2020-04-13 | ORBIMED ADVISORS LLC | Director | C-Conversion | A | Common Stock | 148,922 | 0.00 | — | 148,922 | — | ↗ |
| 2020-04-13 | Nussbaum Ran | Director / 10% Owner | C-Conversion | A | Common Stock | 68,654 | 0.00 | — | 68,654 | — | ↗ |
| 2020-04-13 | Lazarus Alon | Director / 10% Owner | C-Conversion | D | Series C Preferred Stock | 167,537 | 0.00 | — | 0 | — | ↗ |
| 2020-04-13 | Knowles Julius | Director | C-Conversion | A | Common Stock | 205,962 | 0.00 | — | 620,650 | — | ↗ |
| 2020-04-13 | Kariv Tomer | Director / 10% Owner | C-Conversion | A | Common Stock | 663,825 | 0.00 | — | 844,371 | — | ↗ |
| 2020-04-13 | GORDON CARL L | Director | P-Purchase | A | Common Stock | 375,200 | 16.00 | 6.00M | 1,119,812 | — | ↗ |
| 2020-04-13 | Arkin Bio Ventures Limited Partnership | 10% Owner | C-Conversion | D | Series B-1 Preferred Stock | 343,270 | 0.00 | — | 0 | — | ↗ |
| 2020-04-07 | Seehra Jasbir | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 696,569 | 16.00 | 11.15M | 696,569 | — | ↗ |
| 2020-04-07 | Regnante Keith | Officer | A-Award | A | Employee Stock Option (right to buy) | 133,622 | 16.00 | 2.14M | 133,622 | — | ↗ |
| 2020-04-07 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 180,546 | — | ↗ |
| 2020-04-07 | Ordonez Claudia | Officer | A-Award | A | Employee Stock Option (right to buy) | 18,430 | 16.00 | 294.9K | 18,430 | — | ↗ |
| 2020-04-07 | ORBIMED ADVISORS LLC | Director | — | I | Series C Preferred Stock | 148,922 | 0.00 | — | 0 | — | ↗ |
| 2020-04-07 | Nussbaum Ran | Director / 10% Owner | — | I | Series C Preferred Stock | 36,858 | 0.00 | — | 0 | — | ↗ |
| 2020-04-07 | Lazarus Alon | Director / 10% Owner | — | I | Series C Preferred Stock | 167,537 | 0.00 | — | 0 | — | ↗ |
| 2020-04-07 | Lachey Jennifer | Officer | — | D | Common Stock | 0 | 0.00 | — | 27,991 | — | ↗ |
| 2020-04-07 | Knowles Julius | Director | — | I | Common Stock | 0 | 0.00 | — | 138,229 | — | ↗ |
| 2020-04-07 | Kariv Tomer | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 370,853 | — | ↗ |
| 2020-04-07 | GORDON CARL L | Director | — | I | Series C Preferred Stock | 148,922 | 0.00 | — | 0 | — | ↗ |
| 2020-04-07 | Farzan Nima | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-07 | Arkin Bio Ventures Limited Partnership | 10% Owner | — | D | Series A Preferred Stock | 1,382,295 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
433.3K
Shares Outstanding
37.22M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jasbir Seehra, Ph.D. President and Chief Executive Officer | 700.0K | — | 1.43M | — | 398.1K | 15.8K | 2.54M | 56.15% | ↗ |
| 2 | 2025 | Christopher Rovaldi Former President and Chief Operating Officer | 578.9K | — | 871.2K | — | — | 26.0K | 1.48M | 59.02% | ↗ |
| 3 | 2025 | Keith Regnante Chief Financial Officer | 470.4K | — | 464.6K | — | 164.9K | 14.0K | 1.11M | 41.71% | ↗ |
| 4 | 2025 | Esther Cho, Esq. Chief Legal Officer | 459.2K | — | 464.6K | — | 161.0K | 14.0K | 1.10M | 42.28% | ↗ |
| 5 | 2024 | Christopher Rovaldi President and Chief Operating Officer | 539.2K | — | — | 6.13M | 297.0K | 13.8K | 6.98M | 87.81% | ↗ |
| 6 | 2024 | Christopher Rovaldi Former President and Chief Operating Officer | 539.2K | — | — | 6.13M | 297.0K | 13.8K | 6.98M | 87.81% | ↗ |
| 7 | 2024 | Jasbir Seehra, Ph.D. President and Chief Executive Officer | 699.0K | — | — | 5.10M | 455.0K | 14.7K | 6.27M | 81.37% | ↗ |
| 8 | 2024 | Jasbir Seehra, Ph.D. Chief Executive Officer and Chair | 699.0K | — | — | 5.10M | 455.0K | 14.7K | 6.27M | 81.37% | ↗ |
| 9 | 2024 | Yung Chyung, M.D. Chief Medical Officer | 70.6K | 11.3K | — | 5.50M | 56.0K | — | 5.64M | 97.55% | ↗ |
| 10 | 2024 | Keith Regnante Chief Financial Officer | 447.8K | — | — | 1.63M | 197.1K | 13.8K | 2.29M | 71.26% | ↗ |
| 11 | 2024 | Simon Cooper, M.B.B.S. Former Chief Medical Officer | 116.1K | — | — | 1.63M | — | 11.2K | 1.76M | 92.77% | ↗ |
| 12 | 2023 | Jasbir Seehra, Ph.D. Chief Executive Officer and Director | 649.1K | 107.3K | — | 7.81M | 357.5K | 11.7K | 8.93M | 87.40% | ↗ |
| 13 | 2023 | Jasbir Seehra, Ph.D. Chief Executive Officer and Chair | 649.1K | 107.3K | — | 7.81M | 357.5K | 11.7K | 8.93M | 87.40% | ↗ |
| 14 | 2023 | Christopher Rovaldi Chief Operating Officer | 500.0K | — | — | 3.90M | 275.0K | 9.9K | 4.69M | 83.26% | ↗ |
| 15 | 2023 | Christopher Rovaldi President and Chief Operating Officer | 500.0K | — | — | 3.90M | 275.0K | 9.9K | 4.69M | 83.26% | ↗ |
| 16 | 2023 | Simon Cooper, M.B.B.S. Chief Medical Officer | 469.8K | — | — | 1.56M | 206.8K | 7.7K | 2.25M | 69.53% | ↗ |
| 17 | 2023 | Simon Cooper, M.B.B.S. Former Chief Medical Officer | 469.8K | — | — | 1.56M | 206.8K | 7.7K | 2.25M | 69.53% | ↗ |
| 18 | 2023 | Keith Regnante Chief Financial Officer | 434.8K | — | — | 1.56M | 191.4K | 9.9K | 2.20M | 71.05% | ↗ |
| 19 | 2023 | Keith Regnante Chief Financial Officer | 434.8K | — | — | 1.56M | 191.4K | 9.9K | 2.20M | 71.05% | ↗ |
| 20 | 2022 | Jasbir Seehra, Ph.D. Chief Executive Officer and Chair | 610.8K | 60.5K | — | 5.48M | 302.5K | 11.8K | 6.46M | 84.75% | ↗ |
| 21 | 2022 | Jasbir Seehra, Ph.D. Chief Executive Officer and Director | 610.8K | 60.5K | — | 5.48M | 302.5K | 11.8K | 6.46M | 84.75% | ↗ |
| 22 | 2022 | Jasbir Seehra, Ph.D. Chief Executive Officer and Director | 610.8K | 60.5K | — | 5.48M | 302.5K | 11.8K | 6.46M | 84.75% | ↗ |
| 23 | 2022 | Christopher Rovaldi President and Chief Operating Officer | 435.4K | — | — | 3.54M | 235.0K | 38.4K | 4.25M | 83.31% | ↗ |
| 24 | 2022 | Christopher Rovaldi Chief Operating Officer | 435.4K | — | — | 3.54M | 235.0K | 38.4K | 4.25M | 83.31% | ↗ |
| 25 | 2022 | Christopher Rovaldi Chief Operating Officer | 435.4K | — | — | 3.54M | 235.0K | 38.4K | 4.25M | 83.31% | ↗ |
| 26 | 2022 | Simon Cooper, M.B.B.S. Chief Medical Officer | 464.4K | — | — | 1.66M | 184.0K | 5.8K | 2.31M | 71.72% | ↗ |
| 27 | 2022 | Simon Cooper, M.B.B.S. Chief Medical Officer | 464.4K | — | — | 1.66M | 184.0K | 5.8K | 2.31M | 71.72% | ↗ |
| 28 | 2022 | Simon Cooper, M.B.B.S. Former Chief Medical Officer | 464.4K | — | — | 1.66M | 184.0K | 5.8K | 2.31M | 71.72% | ↗ |
| 29 | 2021 | Jasbir Seehra, Ph.D. Chief Executive Officer and Director | 556.8K | — | — | 6.33M | 348.0K | 3.3K | 7.23M | 87.45% | ↗ |
| 30 | 2021 | Jasbir Seehra, Ph.D. Chief Executive Officer and Director | 556.8K | — | — | 6.33M | 348.0K | 3.3K | 7.23M | 87.45% | ↗ |
| 31 | 2021 | Keith Regnante Chief Financial Officer | 401.8K | — | — | 2.44M | 200.9K | 540.00 | 3.05M | 80.21% | ↗ |
| 32 | 2021 | Jennifer Lachey, Ph.D. Chief Scientific Officer | 402.8K | — | — | 2.10M | 201.4K | 540.00 | 2.71M | 77.65% | ↗ |
| 33 | 2020 | Jasbir Seehra, Ph.D. Chief Executive Officer and Director | 521.0K | — | — | 8.71M | 262.7K | 3.5K | 9.50M | 91.71% | ↗ |
| 34 | 2020 | Jennifer Lachey, Ph.D. Chief Scientific Officer | 370.2K | — | — | 3.02M | 154.2K | 521.00 | 3.54M | 85.18% | ↗ |
| 35 | 2020 | Keith Regnante Chief Financial Officer | 323.2K | — | — | 1.90M | 138.0K | 521.00 | 2.36M | 80.46% | ↗ |
| 36 | 2020 | Keith Regnante Chief Financial Officer | 323.2K | — | — | 1.90M | 138.0K | 521.00 | 2.36M | 80.46% | ↗ |
| 37 | 2019 | Jasbir Seehra, Ph.D. Chief Executive Officer and Director | 485.1K | — | — | 15.4K | 194.0K | — | 694.5K | 2.21% | ↗ |
| 38 | 2019 | Jennifer Lachey, Ph.D. Chief Scientific Officer | 294.3K | — | — | 27.0K | 93.0K | — | 414.3K | 6.53% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jasbir S. Seehra | President, Chief Executive Officer & Director | 1M | — |
| Keith C. Regnante | Chief Financial Officer | 649.2K | male |
| Esther Cho | Chief Legal Officer & Secretary | 634.2K | female |
| Lorena Lerner | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KROS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
